title: Effects of calcium, magnesium, low-dose aspirin and low-molecular-weight heparin on the release of PP13 from placental explants.
abstract: BACKGROUND
  Preeclampsia is one of the leading causes for maternal and fetal morbidity. Attempts to prevent preeclampsia have already been made using low-dose aspirin, low-molecular-weight heparin (LMWH), and calcium supplementation. Magnesium sulphate is used at the time of disease to prevent eclampsia. Here we investigated the effect of these agents on PP13 release from placental explants.
  
  
  METHODS
  Placentas harvested after C-section of term or preterm control and preeclampsia cases or first trimester terminations were used to obtain explants. Explants were incubated for 24h with/without respective agents, harvested, weighed and subjected to PP13 determination in the culture medium and the explant. LDH was used to determine viability. Dose response curves were obtained for each drug. P < 0.05 was considered significant.
  
  
  RESULTS
  Exposure to magnesium (0.7-7g/day) slightly decreased PP13 release from controls, and slightly increased it in preeclampsia and first trimester termination. Calcium (0. 3-6g/day) showed a tendency to decrease the release in control and preeclampsia, whereas in first trimester release was increased in a bell-shaped manner. Aspirin (0-250 mg/day) tended to decrease the release in controls but increased it in a bell-shaped manner in first trimester and preeclampsia. LMWH showed no effect from 0 to 80 mg/day in controls but tended to decrease PP13 release in preeclampsia and first trimester.
  
  
  CONCLUSIONS
  This data might point to a beneficial effect of aspirin and calcium supplementation in the first trimester of pregnancy and aspirin at the time of disease, although the interaction with the maternal system still needs to be elucidated.
authors.affiliation: Diagnostic Technologies Ltd., 20692 Yoqneam, Israel.
authors.forename: Y-I
authors.initials: YI
authors.lastname: Grimpel
authors.forename: V
authors.initials: V
authors.lastname: Kivity
authors.forename: A
authors.initials: A
authors.lastname: Cohen
authors.forename: H
authors.initials: H
authors.lastname: Meiri
authors.forename: M
authors.initials: M
authors.lastname: Sammar
authors.forename: R
authors.initials: R
authors.lastname: Gonen
authors.forename: B
authors.initials: B
authors.lastname: Huppertz
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D000925:Anticoagulants / Q000494:pharmacology; D001241:Aspirin / Q000494:pharmacology*; D002118:Calcium / Q000494:pharmacology*; D002478:Cells, Cultured; D005260:Female; D037161:Galectins / Q000378:metabolism*; D005865:Gestational Age; D006495:Heparin, Low-Molecular-Weight / Q000494:pharmacology*; D006801:Humans; D008274:Magnesium / Q000494:pharmacology*; D009924:Organ Culture Techniques; D010920:Placenta / Q000187:drug effects* / Q000378:metabolism; D011247:Pregnancy; D011257:Pregnancy Proteins / Q000378:metabolism*; D055815:Young Adult
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000925:Anticoagulants; D037161:Galectins; D006495:Heparin, Low-Molecular-Weight; C038195:LGALS13 protein, human; D011257:Pregnancy Proteins; D008274:Magnesium; D001241:Aspirin; D002118:Calcium